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Abstract
Purpose: This study aims to evaluate the effect of dimercaptosuccinic acid (DMSA)-coated
superparamagnetic iron oxide (γ-Fe2O3@DMSA) bearing the 2-deoxy-D-glucose (2-DG) ligand
on targeting tumors with high-glucose metabolism.
Procedures: γ-Fe2O3@DMSA and 2-DG-conjugated γ-Fe2O3@DMSA (γ-Fe2O3@DMSA-DG)
were prepared. The glucose consumption of MDA-MB-231 and MCF-7 breast cancer cells and
human mammary epithelial cells (HMEpiCs) was assessed. Cells were incubated with γ-
Fe2O3@DMSA or γ-Fe2O3@DMSA-DG, and MDA-MB-231 cells which exhibited the highest
glucose consumption were used in breast cancer xenografts. Tumor targeting was studied by
magnetic resonance imaging and Prussian blue staining in vivo.
Results: Glucose consumption was highest in MDA-MB-231 and lowest in HMEpiCs. In vitro,
there was significant uptake of γ-Fe2O3@DMSA-DG by MDA-MB-231 and MCF-7 cells within
2 h and this was inhibited by glucose. Uptake of γ-Fe2O3@DMSA-DG was significantly higher in
MDA-MB-231 compared with MCF-7 cells, and there was no obvious uptake of γ-Fe2O3@DMSA
in either cell line. In vivo, γ-Fe2O3@DMSA-DG could be detected in the liver and in tumors post-
injection, while γ-Fe2O3@DMSA was nearly undetectable in tumors.
Conclusions: 2-DG-coated γ-Fe2O3@DMSA improved tumor targeting of γ-Fe2O3@DMSA
which can be assessed by magnetic resonance imaging.
Key words: 2-Deoxy-D-glucose, Superparamagnetic iron oxide, Glucose metabolism, Breast
cancer, Magnetic resonance imaging
Introduction
In the 1920s, Warburg discovered that even in the presence
of ample oxygen, cancer cells prefer to metabolize glucose
by glycolysis. This is seemingly a paradox, since glycolysis,
when compared with oxidative phosphorylation, is a less-
efficient pathway for producing ATP [1]. This phenomenon,
known as the Warburg effect, is defined as the state in which
cancer cells maintain upregulated glycolysis to adapt to
hypoxic conditions caused by solid aggressive tumors that
overgrow the blood supply of the feeding neovasculatures
in vivo [2]. Glycolytic metabolism requires significant
amounts of glucose. Breast cancer cells increase glucose
uptake by increasing the expression of the glucoseCorrespondence to: Xiu Shan; e-mail: 13913433095@163.com
(2016)
transporters (GLUT), predominantly GLUT1, which trans-
port glucose to the intracellular medium [3, 4]. This
propensity is the basis behind the clinical imaging and
staging of tumors via positron emission tomography (PET)
[5, 6]. 2-Deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is
a glucose analog that is used in PET as a diagnostic
compound that targets is taken up by glucose transporters
on tumors and retained in tumors by phosphorylation. This
glucose analog, which permits the quantitative analysis of
glycolysis, is by far the most widely used radiolabeling
marker in the diagnostic work-up of primary tumors,
locoregional recurrence, and distant metastases [7]. Howev-
er, since [18F]FDG emits small amounts of radiation and CT
scanners use X-rays to scan, with radiation being potentially
harmful to humans, we evaluated the effectiveness of using a
magnetic resonance imaging (MRI) contrast agent for tumor
metabolic imaging.
MRI is a highly desirable modality for molecular imaging
because it not only provides high spatial resolution but also
affords excellent soft-tissue contrast. Gadolinium and
superparamagnetic iron oxide (SPIO) particle-based MRI
contrast agents are usually applied in clinical MRI; the former
shortens the T1 time of the tissue, and the latter reduces the T2
time, thereby enhancing MRI contrast. Thus, glucose analog-
modified gadolinium contrast agents have been used in MRI
studies for targeting tumors [8, 9], although gadolinium-based
contrast agents may cause nephrogenic systemic fibrosis and
their magnetic susceptibility is low. However, SPIO particles
can decrease the T2 and T2* relaxation times to achieve
negative tissue contrast. Canet et al. demonstrated that SPIO
particles also caused a strong positive contrast enhancement
using T1-weighted TurboFLASH [10], thereby broadening the
utility of this method. Because SPIO particles have not been
shown to cause major toxicity to humans, glucose analog-
labeled SPIO contrast agents have been employed for targeting
tumors [11, 12].
In a recently published study using 2-deoxy-D-glucose (2-
DG)-modified SPIO particles (2-DG-SPIO) coated with
dimercaptosuccinic acid (DMSA) for targeting MDA-MB-
231 cells, the authors found that cells treated with 2-DG-
SPIO absorbed significantly more iron particles than those
treated with SPIO alone [11]. In this study, we have
evaluated the ability of DMSA-coated γ-Fe2O3@DMSA
bearing 2-DG ligands to improve tumor detection in vivo.
Materials and Methods
Materials
Meso-2,3-DMSA was purchased from Shanghai Beihe Chemicals
Co., Ltd. (Shanghai, China); 2-amino-2-deoxy-D-glucose hydro-
chloride (ADG·HCl) was purchased from Alfa Aesar GmbH & Co.
K G ( K a r l s r u h e , G e r m a n y ) ; l - e t h y l - 3 - ( 3 -
d ime t hy l am inop ropy l ) c a r bod i im id e (EDC) and N -
hydroxysuccinimide (NHS) were purchased from Pierce Chemical
Co. (Chongqing, China).
Synthesis and Characterization of γ-
Fe2O3@DMSA-DG Nanoparticles
γ-Fe2O3@DMSA-DG nanoparticles (NPs) were prepared in three steps:
synthesis of γ-Fe2O3, surface coatingwithDMSA, and conjugation of 2-
DG to the nanoparticles. γ-Fe2O3 was synthesized by chemical co-
precipitation and subsequently stabilized with DMSA as previously
described [12]. Briefly, γ-Fe2O3 (100 mg) was dissolved in chloroform
(10 ml) and triethylamine (50 μl) was added. DMSA (50 mg) was
dissolved in dimethyl sulfoxide (10 ml), which was then added to the γ-
Fe2O3 solution. The resulting final solution was vortexed at 60 °C for
12 h. The resultant sample (γ-Fe2O3@DMSA NPs) constituted a black
precipitate. Next, EDC (1 ml of a 0.5 mM stock) and 1 ml NHS
(2.5 mM) were added to 10 ml of γ-Fe2O3@DMSA NPs (1 mM),
followed by the addition of distilled water (8 ml). Following incubation
for 30 min at room temperature, D-glucosamine HCl (10 ml) was added,
and after 2 h, the solution was purified by overnight dialysis against
distilled water (dialysis tubing, MW=8000–10,000). The final sample
was γ-Fe2O3@DMSA-DGNPs. Details of the synthesis can be obtained
in a report from our research group [13].
Glucose Consumption Assay
The glucose metabolic rate of MDA-MB-231 and MCF-7 breast
cancer cells and human mammary epithelial cells (HMEpiCs) was
assessed using the glucose oxidase-peroxidase (GLU-GOD) assay.
Cells were seeded at a density of 5×105 cells/well in 6-well plates and
cultured for 24 h, after which the culture medium was diluted 10-fold
with phosphate-buffered saline (PBS). As a control, primary culture
medium for the respective cell lines was also diluted 10-fold and
measured in parallel. Each data point was the average of six samples.
The glucose metabolic rate was calculated using the formula [(G0–
G24)×l]/N, where G0 is the glucose concentration of the primary
culture medium, G24 is the glucose concentration of the medium after
cells were cultured for 24 h, l is the quantity of culture medium, and N
is the number of seeded cells.
In Vitro Analysis of 2-DG-SPIO Uptake in Breast
Cancer and HMEpiCs
MDA-MB-231 andMCF-7 cells were purchased from the cell bank of
the Chinese Academy of Sciences (Shanghai, China), and HMEpiCs
and culture medium (MED-0001, SUP-0001) were purchased from
PriCells (Wuhan, China). MDA-MB-231 and MCF-7 cells were
cultured in DMEM supplemented with 10 % fetal bovine serum in a
humidified atmosphere of 5 % CO2 at 37 °C. HMEpiCs were cultured
in MED-0001 supplemented with SUP-0001. Cells were incubated
with 5 ml of culture medium containing γ-Fe2O3@DMSA-DGNPs or
γ-Fe2O3@DMSA NPs at an iron concentration of 0.3 μmol/ml for
different time intervals (10 min, 30 min, 1 h, and 2 h). Competition
experiments were performed by adding 25 mmol/l D-glucose to γ-
Fe2O3@DMSA-DG NPs non-glucose DMEM or MED-0001 growth
medium. After incubation, the culture medium was removed.
Adherent cells were washed three times with PBS (0.1 mol/l, pH
7.4), trypsinized, and centrifuged for 5 min at 2000×g. The number of
cells was determined using a Neubauer counting chamber. For
Prussian blue staining, cells were seeded in six-well plates on glass
coverslips. A total of 1×106 cells were embedded in gelatin (500 μl,
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0.3 % v/v final) at room temperature for MRI measurement; 150 μl of
the cell suspension was transferred into a 96-well plate, and the
absorbance was read at 480 nm using a microplate reader (model 680;
Bio-Rad, OK, USA).
Prussian Blue Staining
Cell monolayers grown on glass coverslips were washed three
times with PBS and subsequently fixed with methanol and acetone
(−20 °C). The fixed cells were incubated with 10 % potassium
ferrocyanide for 5 min, incubated with 10 % potassium ferrocya-
nide in 20 % hydrochloric acid for 30 min, and counterstained with
nuclear fast red.
Determination of Intracellular Iron Content
An ultraviolet colorimetric assay was performed as previously
described [14]. Briefly, cells were washed with PBS, trypsinized,
and dissolved in 30 % v/v HCl at 60 °C for 2 h. Any ferrous
chloride present was oxidized to ferric chloride using 0.1 mg/ml
ammonium persulfate (10 ml). Then, the K4[Fe(CN)6]·3H2O
solution (20 ml) was added for 10 min to form the iron-
thiocyanate complex. An aliquot of this mixture (150 μl) was
transferred into a 96-well plate, and the absorbance was read at
480 nm using a microplate reader. A standard curve was generated
using FeCl3·6H2O solutions of different concentrations under the
same conditions. Each experiment was repeated five times.
MRI and T2 Relaxometry of Cells in Gelatin
T2 MR relaxometry of cells in gelatin was performed using a multi-
echo spin echo pulse sequence [time of repetition (TR)=3000 ms;
time to echo (TE) range=22, 44, 66, 88, …, 330, and 352 ms, 16
echoes; field of view (FOV)=150×73 mm; matrix=256×256; slice
thickness=3 mm; voxel size=9 mm3]. T2 relaxometry was tested
using a T2 map. The T2 map calculation can be found under
Bdynamic analysis,^ a mono-exponential fit without signal offset.
The detailed formula is as follows:
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where TEi is the echo time of image I and wi is the weight of image
i with wi ¼ 1TEi.
MTT Cytotoxicity Test
Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. MDA-MB-231
cells (approximately 105 cells/well) were cultured in 96-well plates
for 2 days. The culture medium was then removed, 100 μl of
growth medium containing γ-Fe2O3@DMSA-DG NPs or γ-
Fe2O3@DMSA NPs (0.3–2.4 μmol/l Fe) was added to each well,
and the cells were incubated for 24 h. For each concentration
group, 10 wells were measured and 10 wells were left untreated as
controls. Following incubation, 10 μl (5 mg/ml) of MTT solution
was added to each well and the plate was incubated for 2 h. The
absorbance of each well was measured at 570 nm on an ELISA
reader. Cell viability was expressed as a percentage of control
([A]test/[A]control×100 %).
Targeting Human MDA-MB-231 Breast Cancer
Xenografts
MDA-MB-231 cells were selected for xenograft experiments as
these cells consume more glucose than MCF-7 cells. All experi-
ments were approved by the governmental review committee on
animal care. Human MDA-MB-231 breast cancer xenografts were
generated by subcutaneous injection of MDA-MB-231 cells (2×105
cells/mouse) in the right neck dorsal region of female nude
(BALB/c) mice (n=24) (Vital River, Beijing, China). Animals
were injected with a contrast agent formulation for imaging when
the tumors were approximately 1 cm in diameter, which occurred
approximately 4 weeks after injection of tumor cells. Animals were
anesthetized by intraperitoneal injection of diazepam (8 μg/g)
(Jiangsu Jumpcan Pharmaceutical Group Co., Ltd., Jiangsu, China)
and ketamine hydrochloride (120 μg/g) (Jiangsu Hengrui Medicine
Co., Ltd., Jiangsu, China).
Contrast Agent Administration
Mice with MDA-MB-231 tumors (n=6) were slowly injected with
γ-Fe2O3@DMSA-DG NPs (300 μmol Fe/kg) in 1000 μl sterilisata
(two tail vein injections of 500 μl with a 30-min interval between
injections). MRI was performed at six intervals (before injection,
1 h, 6 h, 12 h, 24 h, and 48 h post-injection). Control animals (n=6)
were injected with γ-Fe2O3@DMSA NPs at the same dose of Fe,
using the same method.
MRI and Analysis
MRI experiments were performed using a 1.5-T whole-body MR
scanner (MAGNETOM Avanto 1.5 T; Siemens, Munich, Germany)
within a wrist coil. MRI was performed in a coronal plane with a
T2W turbo-spin-echo sequence (TR=5500 ms; TE=100 ms;
FOV=150×73 mm; matrix=256; slice thickness=3 mm; flip
angle=170°; selected B1 filter, prescan normalized for the coil
and image filter).
Prussian Blue Staining
Mice (n=12) were anesthetized and euthanized by cervical
dislocation 24 h after injection. Frozen sections of the tumor,
brain, liver, and muscle were fixed in paraformaldehyde (−20 °C).
For Prussian blue staining, the fixed tissues were incubated in 10 %
potassium ferrocyanide for 5 min and then incubated in 10 %
potassium ferrocyanide in 20 % hydrochloric acid for 30 min,
followed by counterstaining with nuclear fast red.
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Statistical Analysis
All numeric data are expressed as mean±standard error of the
mean. A standard unpaired t test was performed. Analysis of
variance, followed by a posteriori Fisher test, was used to test for
differences in T2 signal intensity (or T2 value) of the brain, liver,
muscle, and tumor after contrast medium injection within the
different groups of mice. p values less than 0.05 were considered
statistically significant. All statistical analyses were performed with
SPSS software, version 17.0 (SPSS Inc., Chicago, USA).
Results
Nanoparticle Characterization
The dispersion of γ-Fe2O3@DMSA NPs and γ-
Fe2O3@DMSA-DG NPs in water produced nanoparticle
aggregates. We previously reported [12] that the average
hydrodynamic diameter of γ-Fe2O3@DMSA NPs and γ-
Fe2O3@DMSA-DG NPs was 154.6±28.3 and 156.2±
28.2 nm, respectively, which was the total diameter of
aggregates and their aqueous layer thickness. Our earlier
work [12] also suggests that no larger aggregates were
generated during the conjugation reaction.
The nanoparticle characterization was reported [12] as
follows: most particles were quasi-spherical; the average
diameter of a single NP core was 10 nm; the γ-
Fe2O3@DMSA-DG NPs were γ crystal; DG was success-
fully functionalized onto the surface of γ-Fe2O3@DMSA
NPs; the molar ratio between Fe and DMSA was 100:2.5;
the numerical ratios between Fe2O3 NPs and DMSA and
DMSA and ADG were 1:516 and 1:1.2, respectively; the
percentage of 2-DG on the surface of γ-Fe2O3@DMSA NPs
was approximately 60 % (carboxyl group: 2-DG=10:6); and
the saturation magnetization values (Ms) for γ-
Fe2O3@DMSA NPs and γ-Fe2O3@DMSA-DG NPs were
48.95 and 49.67 emu/g, respectively.
γ-Fe2O3@DMSA NPs and γ-Fe2O3@DMSA-DG
NPs Uptake in Breast Cancer Cells and HMEpiCs
The level of glucose consumption by MDA-MB-231 cells
([1.39±0.19]×10−4 μmol/cell) was higher than that of MCF-7
cells ([1.12±0.21]×10−4 μmol/cell) after 24 h, whereas
HMEpiCs exhibited the lowest levels of glucose consump-
tion ([7.13±0.08]×10−5 μmol/cell). The difference in glucose
consumption was significant between the three cell lines
(pG0.01).
The uptake of γ-Fe2O3@DMSA NPs, γ-Fe2O3@DMSA-
DG NPs, and γ-Fe2O3@DMSA-DG NPs after blocking the
target by addition of D-glucose was assessed by Prussian
blue staining in cells. After 10 min, strong uptake of γ-
Fe2O3@DMSA-DG NPs was observed in MDA-MB-231
cells and MCF-7 cells. Analysis of blue granules in the
cytoplasm of MDA-MB-231 cells revealed stronger uptake
of γ-Fe2O3@DMSA-DG NPs compared with MCF-7 cells.
Blocking the glucose receptor with free glucose effectively
reduced the absorption of γ-Fe2O3@DMSA-DG NPs in the
cytoplasm of MDA-MB-231 cells and MCF-7 cells, indicat-
ing that the accumulation of these particles was specifically
mediated by binding of glucose to the glucose transporter
(Fig. 1). There was no significant uptake of γ-
Fe2O3@DMSA NPs, γ-Fe2O3@DMSA-DG NPs, or γ-
Fe2O3@DMSA-DG NPs in the presence of glucose in
HMEpiCs in less than 2 h, whereas slight uptake of γ-
Fe2O3@DMSA NPs was observed in MDA-MB-231 and
MCF-7 cells after 1 h.
Quantification of cellular iron content by ultraviolet
colorimetric assay demonstrated a higher uptake of γ-
Fe2O3@DMSA-DG NPs compared with γ-Fe2O3@DMSA
NPs and γ-Fe2O3@DMSA-DG NPs after blocking the
glucose receptor by glucose incubation for the same length
of time, in MDA-MB-231 cells and MCF-7 cells (pG0.05).
However, there were no significant differences between the
cellular iron content of γ-Fe2O3@DMSA NPs and γ-
Fe2O3@DMSA-DG NPs in HMEpiCs (p90.05). The ultra-
violet colorimetric assay also revealed higher uptake of γ-
Fe2O3@DMSA-DG NPs in MDA-MB-231 cells compared
with MCF-7 cells, while HMEpiCs had the lowest uptake
value after the same incubation time (Fig. 2).
These changes were also reflected in the T2 relaxation
times. After 10 min of incubation, the mean T2 relaxation
time of MDA-MB-231 and MCF-7 cells exposed to γ-
Fe2O3@DMSA-DG NPs was significantly shorter than that
of cells incubated with γ-Fe2O3@DMSA NPs (pG0.05),
while there were no significant difference in the mean T2
relaxation time change in the different groups of HMEpiCs
(p90.05). After blocking the binding site with free glucose
and subsequent incubation with γ-Fe2O3@DMSA-DG NPs,
the T2 relaxation times of MDA-MB-231 and MCF-7 cells
were significantly higher than those of MDA-MB-231 and
MCF-7 cells incubated with γ-Fe2O3@DMSA-DG NPs in
non-glucose medium (Fig. 3, Table 1). Furthermore, the T2
relaxation time of MDA-MB-231 cells was significantly
shorter than that of MCF-7 cells incubated with γ-
Fe2O3@DMSA-DG NPs after the same length of incubation
(pG0.05).
The viability values of MDA-MB-231 cells treated with
γ-Fe2O3@DMSA-DG NPs were 100.23±2.26 (0.3 μmol/
ml), 100.19±2.43 (0.6 μmol/ml), 100.11±1.69 (1.2 μmol/
ml), 99.48±2.54 (2.4 μmol/ml), and 99.75±2.73 (4.8 μmol/
ml). The viability of cells treated with γ-Fe2O3@DMSA NPs
was 99.64±1.73 (0.3 μmol/ml), 99.76±2.72 (0.6 μmol/ml),
99.61±1.98 (1.2 μmol/ml), 99.18±2.21 (2.4 μmol/ml), and
97.31±4.02 (4.8 μmol/ml). One-way analysis of variance
revealed no significant differences in cell viability between
the two groups of treated cells (p90.05). The MTT assay did
not demonstrate reduced viability of MDA-MB-231 cells
after incubation with γ-Fe2O3@DMSA NPs or γ-
Fe2O3@DMSA-DG NPs, at variable iron concentrations
for 24 h. These results indicate that γ-Fe2O3@DMSA NPs
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and γ-Fe2O3@DMSA-DG NPs do not inhibit cell growth at
Fe concentrations between 0.3 and 2.4 μmol/ml and
therefore caused no significant cytotoxicity.
Detection of Targeted Tumors
1.5-T Dynamic MRI Tumors exhibited different MRI
features in the two different study groups. In the γ-
Fe2O3@DMSA NPs group, MRI T2-weighted images
showed a decrease in tumor signal intensity 12 h after
injection, which returned to basal levels before injection
after 24 h (Fig. 4). In the γ-Fe2O3@DMSA-DG NPs group,
the T2 weighted images exhibited a decrease in tumor signal
intensity 12–48 h after injection, with the most significant
hypointensity occurring 24 h after injection (Fig. 4). The
signal intensity in the liver significantly decreased 1 h after
injection of γ-Fe2O3@DMSA NPs or γ-Fe2O3@DMSA-DG
NPs, and after which point, the liver retained its
hypointensity. Signal intensity decreased slightly in the
brain at 24 h; however, the mean signal intensity of each
time point in the two groups was not significantly different
in the brain and the signal intensity in the muscle was not
significantly different pre-injection compared with 48 h
post-injection (Fig. 5).
Fig. 1 Prussian blue staining in MDA-MB-231 incubated with a γ-Fe2O3@DMSA-DG NPs, d γ-Fe2O3@DMSA NPs, and g γ-
Fe2O3@DMSA-DG NPs plus glucose for 30 min; MCF-7 incubated with b γ-Fe2O3@DMSA-DG NPs, e γ-Fe2O3@DMSA NPs,
and h γ-Fe2O3@DMSA-DG NPs plus glucose for 30 min; and HMEpiCs incubated with c γ-Fe2O3@DMSA-DG NPs, f γ-
Fe2O3@DMSA NPs, and i γ-Fe2O3@DMSA-DG NPs plus glucose for 30 min. a MDA-MB-231 cells exhibited significantly more
uptake than b MCF-7 cells, and there were no blue granules in the cytoplasm of c HMEpiCs. d MDA-MB-231 cells, e MCF-7
cells, and f HMEpiC incubated with γ-Fe2O3@DMSA NPs displayed almost no granules in the cytoplasm. Glucose transporters
were blocked by addition of free glucose, followed by incubation with γ-Fe2O3@DMSA-DG NPs. Blue granules in the cytoplasm
of g MDA-MB-231 and h MCF-7 cells decreased significantly compared with a and b, respectively.
Fig. 2 Cellular iron content in MDA-MB-231, MCF-7, and
HMEpiCs incubated with γ-Fe2O3@DMSA-DG NPs, γ-
Fe2O3@DMSA NPs, and γ-Fe2O3@DMSA-DG NPs plus
glucose for 30 min, as determined by an ultraviolet colori-
metric assay.
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Uptake of γ-Fe2O3@DMSA NPs and γ-Fe2O3@DMSA-DG
NPs in Tissues Twenty-four hours post-injection, Prussian
blue staining of tumor tissues in the γ-Fe2O3@DMSA
NPs group (n=6) revealed no significant uptake of γ-
Fe2O3@DMSA NPs in tumor cells (Fig. 6). In contrast,
iron particle uptake was observed in tumor cells around
the necrotic site in the γ-Fe2O3@DMSA-DG NPs group
(n=6) (Fig. 6). An abundance of iron particles was also
observed in the liver, but no iron particles were found in
the muscle and brain.
Discussion
Previous studies in which iron oxide particles accumulate in
the reticuloendothelial system but not in tumor cells have
been challenged. Indeed, SPIO particles penetrating the
Fig. 3 Relaxation time mapping of MDA-MB-231, MCF-7, and HMEpiCs incubated with γ-Fe2O3@DMSA-DG NPs, γ-
Fe2O3@DMSA NPs, and γ-Fe2O3@DMSA-DG NPs plus glucose for 30 min. The samples of a MDA-MB-231 and d MCF-7
incubated with γ-Fe2O3@DMSA-DG NPs are shown in black, indicating significant iron particle absorption. Other samples (b, c,
e–i) are displayed in gray, indicating no significant iron particle absorption.
Table 1. T2 relaxation times of MDA-MB-231, MCF-7, and HMEpiCs incubated with γ-Fe2O3-DMSA-DG NPs, γ-Fe2O3-DMSA NPs, and γ-Fe2O3-DMSA-
DG NPs+glucose (mean±SD)
Cells Incubation time (min) γ-Fe2O3@DMSA-DG NPs γ-Fe2O3@DMSA NPs γ-Fe2O3@DMSA-DG NPs+Glu
MDA-MB-231 10 248.40±7.74 294.56±4.42 292.60±3.69
30 202.12±7.22 272.88±11.12 272.78±7.84
60 69.26±6.50 205.20±29.01 224.62±24.60
120 58.66±12.71 164.60±22.30 151.06±15.74
MCF-7 10 260.82±9.25 292.26±9.13 292.76±10.27
30 219.90±8.92 289.88±4.42 287.86±6.36
60 172.96±11.72 278.66±7.98 270.68±11.34
120 175.52±14.45 266.08±5.59 266.78±4.55
HMEpiC 10 299.20±9.55 298.16±6.96 297.02±9.28
30 298.20±6.42 294.98±7.25 296.98±6.90
60 288.80±6.81 288.88±6.28 288.94±8.54
120 282.96±8.23 284.36±7.13 279.88±10.17
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capillary endothelium and tumoral uptake have been
observed [15, 16], particularly when used at higher doses.
These observations are also supported in vitro, in cell culture
studies [17].
In this study, DMSA-coated and 2-DG-conjugated SPIOs
were developed and their ability to target breast cancer cells
with high-glucose consumption was investigated both
in vitro and in vivo. Our results suggest that this design
allows significantly higher in vivo tumor enhancement
compared with unconjugated 2-DG iron oxide nanoparticles
in a human breast cancer xenograft model.
The pharmacokinetics and cellular uptake of SPIOs
in vivo, including their ability to manage biological barriers,
are largely related to NP physicochemical properties,
including morphology, hydrodynamic size, charge, and other
surface properties [18, 19]. NPs consist of a magnetically
active core coated with a stabilizing shell to which target
ligands or ligand analogs, and additional imaging modalities
are anchored, which makes them preferable for biological
applications. DMSA coating provides a significant advan-
tage in that the presence of carboxyl groups on the particle
surface can easily be used to covalently attach specific
ligands or ligand analogs, and the coating layer, which does
not contribute to the MRI signal, can be kept very thin.
The exploitation of GLUT overexpression in tumor cells
and tissues, such as the glucose receptor GLUT1, has
already been successfully harnessed in PET studies with
fluorodeoxyglucose or [99mTc]-DTPA-DG [20–22] and has
been used in MRI with Gd-DTPA-DG [9] and niosomes
bearing glucose conjugates (N-palmitoyl glucosamine) [8].
Glucose receptors are overexpressed in many tumor cells
because of their enhanced metabolism [3, 23]. In this study,
we assessed glucose consumption in MDA-MB-231 and
MCF-7 breast cancer cells and HMEpiCs for 24 h using the
GLU-GOD assay. We found that MDA-MB-231 cells
exhibited the highest level of glucose consumption, while
glucose consumption by HMEpiCs was significantly lower
than that of MCF-7 cells. Data from our in vitro study
showed that the uptake of iron particles in MDA-MB-231
cells was greater than that of MCF-7 cells following
incubation with γ-Fe2O3@DMSA-DG NPs for the same
period of time. There was no significant iron particle uptake
in HMEpiCs incubated with γ-Fe2O3@DMSA-DG NPs
within 2 h. To prove that the particles were absorbed
through the glucose receptors, we blocked the glucose
receptor with free glucose in MDA-MB-231 and MCF-7
cells and then incubated the cells with γ-Fe2O3@DMSA-DG
NPs. This led to a significant decrease in the cellular uptake
of iron particles, suggesting that the uptake of γ-
Fe2O3@DMSA-DG NPs by MDA-MB-231 and MCF-7
cells occurs via glucose receptors that are overexpressed in
these cells.
According to other reports, expression of GLUT1
occurs predominantly around the area of tumor necrosis
Fig. 4 1.5-T MRI turbo-spin-echo-T2-weighted (5500/100) dynamic imaging of human MDA-MB-231 breast cancer
xenografts. a–f Injection of γ-Fe2O3@DMSA NPs showed that the tumor (thick white arrows) signal intensity decreased at
12 h which returned to basal levels by 24 h. g–l Injection of γ-Fe2O3@DMSA-DG NPs showed that the tumor signal intensity
decreased between 12 and 48 h, with the most hypointensity observed at 24 h. The signal intensity in the liver (thin white
arrows) significantly decreased after injection of γ-Fe2O3@DMSA NPs or γ-Fe2O3@DMSA-DG NPs.
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[24, 25]. Our xenograft models had tumor diameters of
approximately 1 cm, because such large tumors usually
contain necrotic areas. Targeted NP drug delivery systems
have shown faster and higher levels of accumulation in
tumors compared with non-targeted systems [26–29]. In
this study, following administration of γ-Fe2O3@DMSA-
DG NPs in mice, 1.5-T MRI revealed that the T2 signal
intensity in tumors decreased from 12 to 48 h. This was
significantly different from the results observed after
administration of γ-Fe2O3@DMSA NPs, where the T2
signal intensity in tumors decreased at 12 h but returned
to basal levels prior to 24 h. Notably, there were no
significant differences in T2 signal intensity between the
two groups in the brain, liver, and muscle. Prussian blue
staining of tumor tissues revealed iron particle uptake in
some tumor cells 24 h after injection of γ-Fe2O3@DMSA-
DG NPs, whereas no significant iron particle uptake was
observed in tumor cells 24 h after injection of γ-
Fe2O3@DMSA NPs. This demonstrates that the targeting
NPs prepared in this study had tumor-specific targeting
aggregation. Thus, the addition of a targeting molecule
onto the surface of NPs increased the selective cellular
binding and internalization through receptor-mediated
active uptake and endocytosis. Without the incorporation
of targeting ligands or ligand analogs, NPs only rely on
nonspecific interactions with cell membranes.
Fig. 5 T2 signal intensity in the a tumor, b brain, c liver, and d muscle (mean±standard error of the mean) after injection of γ-
Fe2O3@DMSA NPs (blue line control group) and γ-Fe2O3@DMSA-DG NPs (green line test group). In the tumor, the predominant
T2 signal intensity decreased at 24 and 48 h in the γ-Fe2O3@DMSA-DG NPs group, which was significantly different to the γ-
Fe2O3@DMSA NPs group. There were no significant differences between the two groups with regard to the brain, liver, and
muscle.
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The results of in vitro experiments may differ signifi-
cantly to those obtained in vivo. In vitro, a number of
particles may surround the tumor cells; however, in vivo,
after intravenous injection, numerous opsonin proteins, cells,
and salts bind to the surface of the nanoparticles. This is
known as the opsonization process and is responsible for
easier recognition by the mononuclear phagocytic system
leading to rapid clearance from the circulation. Nanoparti-
cles are usually taken up by macrophages in the liver
[Kupffer cells (80–90 %), spleen (5–8 %), and bone marrow
(1–2 %)]. After uptake in specialized macrophages, SPIOs
are degraded lysosomally. The nanoparticles internalized by
tumor cells cannot be metabolized and eliminated quickly.
The coating material is eliminated via other decomposition
and elimination pathways. For example, the coating of
ferumoxtran-10 is degraded via intracellular dextranases and
is primarily eliminated renally (89 % in 8 weeks) and the
core material is supplied to the iron storage pool of the body.
The γ-Fe2O3@DMSA-DG NPs or γ-Fe2O3@DMSA NPs
used were non-monodispersed SPIOs, as they were not
connected to active surface molecular polyethylene glycol
and, as such, could not avoid phagocytosis by the reticulo-
endothelial system (RES) in the body. They do not have
identical physical properties for uncontrolled bio-distribution
and bio-elimination. The average hydrodynamic diameter of
the nanoparticle was approximately 150 nm, and a large
number of these particles were taken up by the RES. In our
in vivo study, we observed that the T2-weighted signal in the
liver decreased immediately after injection of γ-
Fe2O3@DMSA-DG NPs or γ-Fe2O3@DMSA NPs,
indicating that most particles were phagocytized by the
RES. If the 2-DG-modified SPIO decreases the both signals
of liver metastasis and the health parts, the liver tumor may
not be easily detected.
However, the biocompatibility of such particles is not
only related to their nano-size but is particularly related to
their surface properties, which are the determining factors
for cellular uptake and cytotoxicity [26]. In addition, coating
materials also play an important role [27], as coating serves
to further functionalization of the particles by ligands or
ligand analogs, helping to facilitate receptor-mediated
endocytosis or phagocytosis [28, 29].
Conclusion
In this study, DMSA-coated naked iron oxide supplied
carboxyl groups, which were linked with D-glucosamine
hydrochloride and X-ray spectroscopy demonstrated that
DG was successfully functionalized onto the surface of γ-
Fe2O3-DMSA NPs. The glucose analog, 2-DG, can bind
to glucose transporters overexpressed in tumor cells. Our
results demonstrated the uptake of γ-Fe2O3@DMSA-DG
NPs by breast cancer cells exhibiting high-glucose
consumption, but no uptake of γ-Fe2O3-DMSA NPs.
These findings indicate that it is possible to non-
invasively identify high-glucose metabolic tumors by
MRI after injection of γ-Fe2O3@DMSA-DG NPs. How-
ever, compared with 18F-FDG PET-CT, one drawback of
this approach is that it requires two MRI scans (before
injection and 24 h after injection).
Fig. 6 Frozen tumor tissue sections with Prussian blue staining 24 h after injection of γ-Fe2O3@DMSA-DG NPs (a, b) and γ-
Fe2O3@DMSA NPs (c, d). The was uptake of iron particles (blue) in tumor cells surrounding the necrotic tumor tissue (a ×1; b
×40), but there was no uptake of iron particles in tumor tissue after injection of γ-Fe2O3@DMSA NPs (c ×1; d ×40).
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